A new theory of Alzheimer’s disease reassesses the role of beta-amyloid in the brain.
(AP Photo/Evan Vucci)
Alzheimer’s may not be primarily a disease of the brain. It may be a disorder of the immune system within the brain. Beta-amyloid may not be an abnormal protein, but part of the brain’s immune system.
Clinical trials of the drug have shown mixed results.
More research is needed to prove the drug slows cognitive decline.
Atthapon Raksthaput/ Shutterstock
The first drug targeting Alzheimer’s disease has been approved in 20 years – but its approval isn’t based on substantial evidence.
Do the benefits of approving a drug before confirming it works outweigh the potential costs?
monkeybusinessimages/iStock via Getty Images Plus
The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.
Trials for new Alzheimer’s drugs have been failing a lot, lately. But it may be premature to abandon these drugs altogether.
A lot of Alzheimer’s treatments focus on removing plaques in the brain. But could this be the wrong target?
Family members often become primary caregivers for loved ones with Alzheimer’s disease.
The first clinical trial examining a drug to treat Alzheimer’s was begun 30 years ago. There is still no cure and no known way to prevent the disease. Two factors may contribute to that.
A bottlenose dolphin leaping from the ocean in Panama.
Researchers have found evidence of the same brain pathologies in dolphins that are present in the brains of humans who died with Alzheimer’s. What might this suggest about Alzheimer’s in humans?